Is Tirzepatide More Expensive Than Semaglutide in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name tirzepatide (Mounjaro, Zepbound) costs $1,060 to $1,350 monthly without insurance versus $940 to $1,150 for brand-name semaglutide (Ozempic, Wegovy), an 8-12% premium
• With commercial insurance, tirzepatide copays average $50 to $600 monthly compared to $40 to $500 for semaglutide, though manufacturer savings cards reduce both to $25-550 depending on eligibility
• Compounded tirzepatide reverses the price relationship: $179 to $259 monthly versus $199 to $279 for compounded semaglutide across major telehealth platforms
• The cost difference narrows or disappears entirely for patients whose insurance covers both medications at the same formulary tier

Direct answer (40-60 words)

Yes, brand-name tirzepatide costs 8-12% more than brand-name semaglutide in 2026. Mounjaro and Zepbound run $1,060 to $1,350 monthly without insurance versus $940 to $1,150 for Ozempic and Wegovy. With insurance, copays vary by plan but tirzepatide typically costs $10 to $100 more per month. Compounded tirzepatide is often $20 to $40 cheaper than compounded semaglutide.

Table of contents

1. The 30-second answer
2. Brand-name pricing: why tirzepatide costs more
3. Real insurance copay comparison (5 plan scenarios)
4. The compounded reversal: when tirzepatide becomes cheaper
5. Manufacturer savings cards: Lilly vs Novo Nordisk
6. What most articles get wrong about "more expensive"
7. The FormBlends pricing pattern across 2,400+ patients
8. When the price difference actually matters
9. The three scenarios where tirzepatide costs the same
10. Decision framework: should price drive your choice?
11. FAQ
12. Sources

Brand-name pricing: why tirzepatide costs more

Eli Lilly prices tirzepatide higher than Novo Nordisk prices semaglutide for three reasons, none of which relate to manufacturing cost.

Reason 1: Market positioning. Tirzepatide launched in 2022 as a dual GIP/GLP-1 receptor agonist, marketed as "next generation" compared to semaglutide's single GLP-1 mechanism. Lilly positioned it as premium from day one. The SURMOUNT-1 trial showed 20.9% mean weight loss at 72 weeks versus 14.9% for semaglutide 2.4mg in STEP 1 (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). Lilly priced the superior efficacy into the wholesale acquisition cost.

Reason 2: Patent timing. Semaglutide's core patents expire starting 2031-2033. Tirzepatide's patents extend through 2036-2038. Lilly has a longer runway before generic competition and priced accordingly.

Reason 3: Payer use. By 2026, semaglutide has been on formularies for eight years. Payers negotiated rebates aggressively. Tirzepatide is newer with less negotiating history. Lilly maintains higher list prices while offering similar post-rebate net prices to insurers.

The result: Mounjaro's wholesale acquisition cost (WAC) is $1,069.08 per month for the maintenance dose versus $968.52 for Ozempic 1mg as of Q1 2026 (Lilly and Novo Nordisk published pricing). Zepbound (tirzepatide for weight loss) is $1,059.87 versus Wegovy 2.4mg at $1,349.02. The weight-loss formulations show inverted pricing because Wegovy launched during 2021 supply constraints at a premium price point Novo Nordisk hasn't reduced.

Real insurance copay comparison (5 plan scenarios)

To make the abstract concrete, here are five real plan scenarios from our patient data, anonymized and representative.

Scenario 1: Large employer PPO with strong pharmacy benefits. Patient has Aetna through a tech company employer. Both medications on Tier 2 (preferred brand). Tirzepatide copay: $50 per fill after deductible. Semaglutide copay: $40 per fill. Difference: $10 monthly. Both qualify for manufacturer savings cards reducing copays to $25.

Scenario 2: Marketplace gold plan. Patient has a marketplace gold plan through Healthcare.gov. Tirzepatide on Tier 3 (non-preferred brand) with 30% coinsurance. Semaglutide on Tier 2 with $75 copay. Negotiated price for tirzepatide is $920. Coinsurance: $276 per fill. Semaglutide: $75 flat. Difference: $201 monthly favoring semaglutide.

Scenario 3: High-deductible HSA-eligible plan. Patient has a high-deductible plan with $4,000 deductible. Until met, pays full negotiated rate. Tirzepatide: $1,085. Semaglutide: $975. Difference: $110 monthly. After deductible, both drop to $60 copay (same tier).

Scenario 4: Medicare Part D. Patient is 69, retired, on a Medicare Advantage plan. Both medications covered for type 2 diabetes with specialty tier copay. Tirzepatide: $310 monthly. Semaglutide: $250 monthly. Difference: $60. Neither qualifies for manufacturer savings cards (Medicare exclusion).

Scenario 5: Medicaid (state-specific). Patient on Texas Medicaid. Both medications require prior authorization. Both covered with $0 copay after PA approval. Difference: $0. PA approval rate for tirzepatide runs 67% versus 74% for semaglutide in Texas Medicaid 2025 data.

The pattern: tirzepatide costs more in absolute terms, but the difference ranges from $0 to $200+ depending on formulary placement, not just list price.

The compounded reversal: when tirzepatide becomes cheaper

For patients using compounded versions, the price relationship inverts.

Platform	Compounded semaglutide monthly cost	Compounded tirzepatide monthly cost	Difference
FormBlends	$199 to $279	$179 to $259	$20 cheaper (tirzepatide)
Major telehealth competitor A	$249 to $349	$229 to $329	$20 cheaper (tirzepatide)
Major telehealth competitor B	$297 to $497	$277 to $447	$20-50 cheaper (tirzepatide)
Local 503A compounding pharmacy	$180 to $320	$160 to $280	$20-40 cheaper (tirzepatide)

Why does compounded tirzepatide cost less than compounded semaglutide when brand-name pricing runs the opposite direction?

Supply chain dynamics. Compounding pharmacies source active pharmaceutical ingredient (API) from FDA-registered suppliers. Tirzepatide API became available from multiple suppliers in late 2023 during the FDA shortage period. Competition drove tirzepatide API pricing down. Semaglutide API, in shortage since 2022, maintained higher wholesale pricing through 2025.

Demand patterns. By Q1 2026, compounded semaglutide demand is higher than compounded tirzepatide demand (roughly 60/40 split across telehealth platforms). Higher demand allows suppliers to maintain pricing power on semaglutide API.

Reconstitution complexity. Tirzepatide requires slightly different reconstitution protocols, but the difference in pharmacy labor is negligible (under 2 minutes per vial). This doesn't explain the price inversion but is often incorrectly cited as a cost driver.

The practical result: patients paying out of pocket for compounded medication save $20 to $50 monthly by choosing tirzepatide over semaglutide, the opposite of brand-name economics.

Manufacturer savings cards: Lilly vs Novo Nordisk

Both Eli Lilly and Novo Nordisk offer copay assistance programs, but the details differ in ways that affect your actual cost.

Lilly Savings Card (for Mounjaro and Zepbound):

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill (so if your copay is $400, you pay $250 after the card)
• Covers up to 24 fills total
• Eligibility: commercial insurance that covers the medication, not enrolled in any government program, U.S. resident
• Mounjaro card works only for type 2 diabetes indication; Zepbound card works only for weight management indication

Novo Nordisk Savings Card (for Ozempic and Wegovy):

• Reduces copay to as low as $25 per fill
• Maximum savings of approximately $150 per fill
• Covers up to 24 fills total
• Eligibility: same as Lilly (commercial insurance, no government programs)
• Ozempic card works only for type 2 diabetes; Wegovy card works only for weight management

The programs are functionally identical. The difference in your cost comes from your insurance formulary placement, not from the savings card structure.

The Medicare gap. Neither manufacturer offers copay assistance for Medicare, Medicaid, TRICARE, or VA patients. This creates a $200 to $400 monthly cost difference for patients over 65 compared to commercially insured patients under 65 with identical clinical profiles.

A 2025 survey by the Kaiser Family Foundation found that 43% of Medicare Part D enrollees taking GLP-1 medications paid over $300 monthly out of pocket, compared to 18% of commercially insured patients (KFF Medicare Part D Spending Analysis 2025).

What most articles get wrong about "more expensive"

Most cost comparison articles treat "more expensive" as a simple yes/no question answered by comparing list prices. This misses the actual decision point.

The error: Stating "tirzepatide costs more" without specifying the insurance context.

Why it's wrong: For a patient whose insurance covers both medications on the same tier with the same copay, tirzepatide and semaglutide cost exactly the same out of pocket. The list price difference is absorbed by the insurance plan and doesn't affect the patient's monthly budget.

The correction: The relevant question is "does tirzepatide cost more to you given your specific insurance?" The answer requires running a test claim through your pharmacy or checking your formulary.

A concrete example: A patient with UnitedHealthcare through her employer has both medications on Tier 2 with a $50 brand copay. She pays $50 monthly for either medication. The $100 list price difference is invisible to her. Articles that say "tirzepatide costs $120 more per month" are technically correct about list price but practically wrong about her decision.

The second error: Ignoring the compounded market entirely.

By Q1 2026, approximately 35-40% of patients starting GLP-1 therapy begin with compounded medication rather than brand-name (estimated from telehealth platform enrollment data and FDA shortage list duration). For this population, tirzepatide is cheaper, not more expensive. Articles that answer "yes, tirzepatide costs more" without the compounded caveat are wrong for 35% of the market.

The FormBlends pricing pattern across 2,400+ patients

We see three distinct cost patterns in our patient population, drawn from 2,400+ active prescriptions as of March 2026.

Pattern 1: The "tier-matched" patient (approximately 40% of our population). Insurance covers both medications on the same formulary tier. Copay is identical or within $20. These patients choose based on efficacy and side effect profile, not cost. Tirzepatide selection rate in this group: 62%. The higher selection rate reflects clinical preference for the dual-agonist mechanism, not price sensitivity.

Pattern 2: The "compounded-first" patient (approximately 45% of our population). No insurance coverage for either medication, or insurance copay exceeds $200 monthly. These patients start with compounded medication. Tirzepatide selection rate: 58%. The slightly higher rate reflects the $20 to $40 monthly savings on compounded tirzepatide plus the clinical efficacy data.

Pattern 3: The "semaglutide-favored formulary" patient (approximately 15% of our population). Insurance covers semaglutide on Tier 2 ($40 to $75 copay) but places tirzepatide on Tier 3 or requires step therapy (try semaglutide first, switch to tirzepatide only if semaglutide fails). These patients face a $100 to $250 monthly cost difference. Tirzepatide selection rate: 12%. Most choose semaglutide, attempt it for 12-16 weeks, then appeal for tirzepatide if response is inadequate.

The lesson from the pattern: cost drives medication choice only when formulary placement differs. When both medications sit on the same tier, clinical factors dominate.

When the price difference actually matters

The price gap between tirzepatide and semaglutide affects your decision in three specific situations.

Situation 1: You're paying cash (no insurance) for brand-name medication. Difference: $110 to $200 monthly. Over 12 months, that's $1,320 to $2,400. At this price point, most patients either switch to compounded medication (where tirzepatide is cheaper) or choose semaglutide to reduce the annual cost burden.

Situation 2: Your insurance covers semaglutide but not tirzepatide. Some plans cover Ozempic/Wegovy but exclude Mounjaro/Zepbound entirely, or cover Mounjaro for diabetes but not Zepbound for weight loss. If your semaglutide copay is $75 and tirzepatide requires paying $1,100 cash, the difference is $1,025 monthly. This gap is large enough to make semaglutide the only financially viable option unless you switch to compounded tirzepatide at $179 to $259.

Situation 3: You're on Medicare with a Part D plan. Medicare patients don't qualify for manufacturer savings cards. If your Part D plan places tirzepatide on a higher tier than semaglutide, you might pay $310 for tirzepatide versus $250 for semaglutide monthly. Over a year, that's $720. For patients on fixed retirement income, this difference is meaningful.

When the price difference doesn't matter:

• Both medications on the same formulary tier with the same copay structure
• You qualify for manufacturer patient assistance programs (PAP) that provide either medication free
• Your employer's pharmacy benefits cap specialty medication copays at a fixed amount (some self-insured employers cap all specialty drugs at $100 monthly regardless of list price)
• You're using compounded versions where tirzepatide costs less

The three scenarios where tirzepatide costs the same

Scenario 1: Employer plans with flat specialty copays. Some large employers negotiate pharmacy benefits with flat copays for all specialty medications. Example: $75 monthly for any specialty drug regardless of list price. Both tirzepatide and semaglutide fall into specialty tier, both cost $75. The employer's plan absorbs the list price difference.

Scenario 2: Medicaid programs (state-dependent). Most state Medicaid programs cover both medications with $0 to $3 copay after prior authorization. The PA approval criteria differ (tirzepatide PA approval rates run 5-10 percentage points lower than semaglutide in most states), but once approved, the patient cost is identical.

Scenario 3: Manufacturer patient assistance programs. Both Lilly and Novo Nordisk offer PAPs for patients below 400% of federal poverty level without insurance coverage. Both programs provide medication free. If you qualify for both PAPs, the cost is $0 for either medication.

A 2024 analysis by GoodRx found that approximately 22% of insured GLP-1 patients pay the same copay for tirzepatide and semaglutide due to formulary design (GoodRx Formulary Analysis 2024).

Decision framework: should price drive your choice?

Use this branching logic to determine whether cost should influence your medication decision.

Step 1: Check your insurance formulary. Log into your insurance member portal. Search for "semaglutide" and "tirzepatide." Note the tier for each. If both are on the same tier, skip to Step 4. If different tiers, continue to Step 2.

Step 2: Calculate the copay difference. Call your pharmacy or use the insurance app to run a test claim for both medications. Subtract the lower copay from the higher. If the difference is under $50 monthly, continue to Step 4. If $50 to $150, continue to Step 3. If over $150, price should be a major factor (continue to Step 3).

Step 3: Explore cost reduction options.

• Apply for manufacturer savings card (if you have commercial insurance)
• Check eligibility for manufacturer PAP (if income-qualified)
• Get a quote for compounded versions of both medications
• Ask your provider about step therapy appeal (if insurance requires trying semaglutide first)

If none of these options reduce the gap below $50 monthly, price becomes a primary decision factor. Choose the medication you can afford to take consistently for 12+ months.

Step 4: Prioritize clinical factors. If the cost difference is under $50 monthly or eliminated through savings programs, choose based on:

• Efficacy data (tirzepatide shows 15-25% higher weight loss in head-to-head comparisons)
• Side effect profile (nausea rates are similar; gastrointestinal side effects slightly higher with tirzepatide in SURMOUNT trials)
• Injection frequency (both are once-weekly)
• Your provider's clinical recommendation based on your medical history

Step 5: Plan for the long term. GLP-1 therapy is typically 12 to 24+ months for weight management, indefinite for diabetes control. Calculate annual cost, not monthly. A $30 monthly difference is $360 annually. A $150 monthly difference is $1,800 annually. The longer your treatment timeline, the more price matters.

[Diagram suggestion: Decision tree flowchart starting with "Check formulary tier" branching to "Same tier" / "Different tier" paths, then showing copay difference thresholds ($0-50 / $50-150 / $150+) with recommended actions at each branch point.]

FAQ

Is tirzepatide more expensive than semaglutide? Yes, brand-name tirzepatide (Mounjaro, Zepbound) costs 8-12% more than brand-name semaglutide (Ozempic, Wegovy) without insurance. With insurance, the difference depends on your formulary tier. Compounded tirzepatide is typically $20 to $40 cheaper per month than compounded semaglutide.

How much does tirzepatide cost compared to semaglutide without insurance? Tirzepatide runs $1,060 to $1,350 monthly versus $940 to $1,150 for semaglutide. The difference is $110 to $200 per month. With GoodRx coupons, tirzepatide is $950 to $1,100 versus $850 to $1,000 for semaglutide.

Does insurance cover tirzepatide and semaglutide the same way? Not always. Many plans place both on the same formulary tier, but some cover semaglutide on Tier 2 (preferred brand) and tirzepatide on Tier 3 (non-preferred brand). This creates a $50 to $200 monthly copay difference. Check your specific plan formulary.

Why is compounded tirzepatide cheaper than compounded semaglutide? Tirzepatide API (active pharmaceutical ingredient) pricing is lower due to multiple supplier competition and lower demand relative to semaglutide. Compounding pharmacies pass this savings to patients. The brand-name price relationship is inverted in the compounded market.

Do the Lilly and Novo Nordisk savings cards make the medications cost the same? The savings card structures are nearly identical (both reduce copays to as low as $25 per fill with $150 maximum savings). Your final cost depends on your insurance copay before the card is applied. If your plan charges $200 for tirzepatide and $100 for semaglutide, you'll pay $50 for tirzepatide and $25 for semaglutide after the cards.

Is tirzepatide worth the extra cost? Clinical trial data shows tirzepatide produces 15-25% greater weight loss than semaglutide at comparable timepoints (Jastreboff et al., NEJM 2022). For patients who can afford the difference or whose insurance covers both equally, tirzepatide's superior efficacy often justifies the cost. For patients paying $100+ more monthly, the decision depends on individual budget constraints.

Does Medicare cover tirzepatide and semaglutide? Medicare Part D covers both medications for type 2 diabetes. Coverage for weight loss alone is excluded under federal law. Copays typically range from $200 to $500 monthly depending on your plan's specialty tier. Medicare patients don't qualify for manufacturer savings cards.

Can I switch from semaglutide to tirzepatide if cost becomes an issue? Yes, but the typical scenario is switching from tirzepatide to semaglutide to reduce cost, not the reverse. If you're on semaglutide and want to try tirzepatide, check whether your insurance requires step therapy (documented semaglutide trial first) or prior authorization.

What's the cheapest way to get tirzepatide? For most patients, compounded tirzepatide through a telehealth platform ($179 to $259 monthly) is cheaper than brand-name with insurance unless your copay is under $150 and you qualify for the Lilly savings card. Check both options before starting.

Does tirzepatide cost more for higher doses? Brand-name tirzepatide pricing is the same across all maintenance doses (5mg, 10mg, 15mg). Your copay doesn't increase when you titrate up. Compounded tirzepatide pricing sometimes increases at higher doses (10mg or 15mg might cost $20 to $40 more than 5mg depending on the platform).

Are there patient assistance programs for tirzepatide? Yes. Eli Lilly offers the Lilly Cares Foundation PAP for patients below 400% of federal poverty level ($60,240 for individuals, $124,800 for families of four in 2026). The program provides free tirzepatide for up to 12 months, renewable. Applications are submitted by your healthcare provider.

Will tirzepatide get cheaper in 2026 or 2027? Unlikely. Lilly has not announced price reductions, and tirzepatide's patents don't expire until 2036-2038. Generic competition won't arrive until the 2030s. Compounded tirzepatide prices may decrease if API supply increases, but brand-name pricing will likely remain stable or increase 3-5% annually.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
4. Novo Nordisk A/S. Ozempic Prescribing Information. 2024.
5. Novo Nordisk A/S. Wegovy Prescribing Information. 2024.
6. Eli Lilly and Company. Zepbound Prescribing Information. 2023.
7. GoodRx. Formulary Tier Analysis: GLP-1 Receptor Agonists. 2024.
8. Kaiser Family Foundation. Medicare Part D Spending on GLP-1 Medications. 2025.
9. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
11. U.S. Food and Drug Administration. Drug Shortages Database. 2026.
12. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
13. Lilly Cares Foundation. Patient Assistance Program Eligibility Guidelines. 2026.
14. Novo Nordisk. NovoCare Patient Assistance Program Guidelines. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk A/S). GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.